TD Cowen analyst Yaron Werber maintained a Buy rating on Nuvation Bio (NUVB – Research Report) today. The company’s shares closed today at $3.30.
Werber covers the Healthcare sector, focusing on stocks such as Amgen, Ionis Pharmaceuticals, and Ultragenyx Pharmaceutical. According to TipRanks, Werber has an average return of 17.2% and a 56.00% success rate on recommended stocks.
Currently, the analyst consensus on Nuvation Bio is a Strong Buy with an average price target of $6.60.
The company has a one-year high of $4.16 and a one-year low of $0.95. Currently, Nuvation Bio has an average volume of 1.48M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nuvation Bio (NUVB) Company Description:
Panacea Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Read More on NUVB:
